Day 1 - Monday, 28 September 2020 | |||
| 10:00 AM | Opening remarks
Jennifer Kiser PharmD, PhD
| |
Session 1: COVID-19 Session | |||
10:10 AM |
Emerging infections and Biosecurity | ||
| 10:30 AM EDT |
COVID-19 Treatment | ||
| 10:50 AM EDT |
Role of Pharmacology of Selection COVID-19 Candidates | ||
| 11:10 AM EDT |  FDA Perspective on COVID-19 Kimberly Struble Food & Drug Administration, Washington, USA | ||
| 11:30 AM EDT | Faculty discussion | ||
| 12:00 PM EDT | Virtual Coffee Break | Meet Your Colleagues | ||
| Session 2: Abstracts Session | |||
| 12:30 PM EDT | Oral Abstract Presentations | ||
| Steady-State Plasma TFV/FTC Among Adolescent Transgender Men and Women Receiving Directly Observed Daily TDF/FTC Jenna Yager, University of Colorado, USA | |||
| Plasma and Breastmilk Pharmacokinetics of Tenofovir Using Dried Blood and Breast Milk Spots in HIV Infected Postpartum Women in Uganda Letisha Najjemba, Infectious Disease Institute, Uganda | |||
| Time Course of Tenofovir-Diphosphate Carryover in DBS Following TDF to TAF Switch Kristina Brooks, University of Colorado, USA | |||
| 01:00 PM EDT | Live Q&A with Abstract Presenters | ||
| 01:15 PM EDT | Oral Poster Presentations | ||
| TFVdp/FTCtp Concentrations in Rectal Samples: No Correlation Between Epithelial Cells Collected by Cytobrush and Isolated CD4+ Cells Mackenzie Cottrell, UNC Eshelman School of Pharmacy, USA | |||
| Mechanistic Modelling for the Quantitative Evaluation Fazila Bunglawala, University of Liverpool, UK | |||
| Intracellular EFdA Pharmacology Differs Between Species: Implications for Preclinical Study Design Mackenzie Cottrell, UNC Eshelman School of Pharmacy, USA | |||
| Inflammation Affects Antiretrovirals Plasma and Intracellular Exposure Micol Ferrara, Ospedale Amedeo Di Savoia, Italy | |||
| 01:35 PM EDT | Live Q&A with Abstract Presenters | ||
| 01:45 PM EDT | End of first day | ||
| Online Networking Opportunities & E-Poster Viewing | |||
| Online Networking | E-poster Viewing plus live chat with presenters | |||
Day 2 - Tuesday, 29 September 2020 | |||
| Session 3: Management of New Antivirals | |||
| 10:00 AM EDT |
Pharmacology of bNABs | ||
| 10:20 AM EDT |
Clinical Pharmacology Long Acting ARVs | ||
| 10:40 AM EDT |
Development of Novel Formulations/Devices | ||
| 11:00 AM EDT | Faculty Discussion | ||
| 11:30 AM EDT | Virtual Coffee Break | Meet Your Colleagues | ||
| Session 4: Abstracts Session | |||
| 12:00 PM EDT | Oral Abstract Presentations - Population PK | ||
| Population Pharmacokinetics of HIV-Specific Broadly Monoclonal Neutralizing Long-Acting Antibody, VRC01LS, in Term Infants Jincheng Yang, University of California San Diego, USA | |||
| In-Silico Prediction of Intramuscular Long-Acting Rilpivirine in Liver Impairment With PBPK Models Nicolas Cottura, University of Liverpool, UK | |||
| 12:30 PM EDT | Live Q&A with Abstract Presenters | ||
| 12:25 PM EDT | Oral Poster Presentations | ||
Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 (GSK’254) and Oral Contraceptive (OC) Ethinyl Estradiol (EE)/Levonorgestrel Pbpk Models Lack of a Pharmacokinetic (PK) Interaction Between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Dolutegravir Open-Label, Drug-Drug Interaction Study between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) in Healthy Participants | |||
| Antiretroviral Drug-drug Interaction (DDI) Profile of Long-acting Cabotegravir and Rilpivirine Parul Patel, ViiV Healthcare, USA | |||
| Fostemsavir Drug-Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Patients With Multidrug Resistant HIV-1 Infection Katy Moore, ViiV Healthcare, USA | |||
| Pharmacokinetics, Safety, and Tolerability of Single- and Multiple Ascending Doses of JNJ-64417184, a Non-Nucleoside Inhibitor of Respiratory Syncytial Virus Polymerase, in Healthy Volunteers Mina Pastagia, Janssen Biopharma, USA | |||
| Single-Ascending Dose (SAD) Pharmacokinetics of Hepatitis B Virus (HBV)-Specific JNJ-73763989 in Non-Japanese and Japanese Healthy Volunteers (HV) Thomas Kakuda, Janssen Biopharma, USA | |||
| Effect of Multiple-Dose Itraconazole on the Pharmacokinetics of Single-Dose JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Volunteers Joris Vandenbossche, Janssen Biopharma, USA | |||
| 01:00 PM EDT | Live Q&A with Abstract Presenters | ||
| 01:15 PM EDT | End of second day | ||
| Online Networking Opportunities & E-Poster Viewing | |||
| Online Networking | E-poster Viewing plus live chat with presenters | |||
Day 3 - Wednesday, 30 September 2020 | |||
| Session 5: Topic for Discussion | |||
| 10:00 AM EDT |
Perspectives on the Use of Endogenous Biomarkers to Assess Transporter Mediated Drug-Drug Interactions (DDIs) | ||
| 10:25 AM EDT |
Role of herbal in DDIs | ||
| 10:50 AM EDT | Faculty discussion | ||
| 11:05 AM EDT | Virtual Coffee Break | Meet Your Colleagues | ||
| Session 6: Abstracts Session | |||
| 11:35 AM EDT | Oral Abstract Presentations - Special Populations - Pediatrics | ||
| Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age Mina Nikanjam, University of California San Diego, USA | |||
| A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIV Vera Bukkems, Radboudumc, Netherlands | |||
| Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets Rajendra Singh, Glaxosmithkline, USA | |||
| 12:05 PM EDT | Live Q&A with Abstract Presenters | ||
| 12:20 PM EDT | Oral Poster Presentations - Special Populations | ||
| Ledipasvir PK-PD (Pharmacokinetics - Pharmacodynamics): Relationship between drug exposure and sustained virologic response rates in a cohort of patientsRelationship Between Drug Exposure and Sustained Virologic Response Rates in a Cohort of Patients Omar Elsherif, Queen Elizabeth Hospital Birmingham, UK | |||
| Exploring the Role of Age in Transporter-Related Drug-Drug Interactions Hannah Kinvig, University of Liverpool, UK | |||
| Genetic Associations With Weight Gain Among South Africans Who Initiated Dolutegravir- and Tenofovir-Containing Regimens in the ADVANCE Study Zinhle Cindi, University of Cape Town, South Africa | |||
| Rifabutin Pharmacokinetics and Safety Among TB/HIV Coinfected Young Children Receiving Lopinavir Holly Rawizza, Brigham and Women's Hospital, USA | |||
| Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers: A Preliminary Jomy George, National Institutes of Health, USA | |||
| 12:45 PM EDT | Live Q&A with Abstract Presenters | ||
| 12:55 PM EDT | Closure - Best of Abstracts Awards | ||
| 01:00 PM EDT | End of the Virtual Workshop | ||
